Maximal Use Study of Tapinarof Cream 1% in Subjects with Extensive Plaque Psoriasis

Main Article Content

John Jett
Michael McLaughlin
Mark Lee
Lawrence Parish
Glenn Tabolt
Timothy Wilson
Matthew Somerville
Wayne DellaMaestra
Stephen Piscitelli


Psoriasis, Aryl Hydrocarbon Receptor Modulating Agent, Tapinarof, Topical


Abstract not available.


1. Menter A, et al. J Am Acad Dermatol. 2008;58:826–850;

2. Garnett C, et al. J Pharmacokinet Pharmacodyn. 2018;45:383–397;

3. Robbins K, et al. J Am Acad Dermatol. 2019;80:714–721;

4. Stein Gold L, et al. J Am Acad Dermatol. 2020; doi: 10.1016/j.jaad.2020.04.181

Most read articles by the same author(s)